Knight Therapeutics Inc. (TSE:GUD) Director Samira Sakhia Purchases 20,000 Shares

Knight Therapeutics Inc. (TSE:GUD) Director Samira Sakhia bought 20,000 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were bought at an average cost of C$5.15 per share, with a total value of C$103,000.00.

Knight Therapeutics Trading Up 0.8 %

Shares of TSE:GUD opened at C$5.15 on Thursday. Knight Therapeutics Inc. has a 1 year low of C$5.07 and a 1 year high of C$6.23. The firm has a fifty day moving average price of C$5.72 and a 200 day moving average price of C$5.74. The company has a current ratio of 3.41, a quick ratio of 1.79 and a debt-to-equity ratio of 7.62. The stock has a market capitalization of C$521.23 million, a PE ratio of -25.75, a P/E/G ratio of -1,013.50 and a beta of 0.50.

Wall Street Analysts Forecast Growth

GUD has been the subject of several recent research reports. Stifel Nicolaus upgraded Knight Therapeutics from a “hold” rating to a “buy” rating and increased their price objective for the stock from C$5.75 to C$6.75 in a report on Tuesday, August 13th. Stifel Canada raised Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 12th.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.